---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-091691"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2026-08-06T12:30:36+00:00"
generated_at: "2026-08-06T12:35:26.805832+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ocugen Q2 net loss $0.07/sh; closes $130M notes; OCU410 Phase 3 cleared by FDA

## Summary
- Net loss $24.9M ($0.07/sh) vs $14.7M ($0.05/sh) in Q2 2025; operating expenses $17.9M.
- Cash $100.4M as of June 30, 2026; closed $130M 6.75% convertible notes due 2034, net $112.5M.
- FDA clearance to initiate OCU410 Phase 3 for geographic atrophy; RMAT designation granted.
- Signed binding term sheet with Roots Pharmaceutical for OCU400 license in MENA: up to $255M milestones + 22% royalty.
- OCU400 RP Phase 3 enrollment complete (N=140); topline Q1 2027. OCU410ST Stargardt enrollment complete (63 subjects); topline Q2 2027.

## SEC filing metadata
- accession: 0001104659-26-091691
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2026-08-06T12:30:36+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000110465926091691/0001104659-26-091691-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000110465926091691/tm2622368d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-091691
- JSON: https://secwatch.observer/filing/0001104659-26-091691.json
- Plain text: https://secwatch.observer/filing/0001104659-26-091691.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.